On Nov. 19, 2020, XBiotech announced data for its breakthrough candidate therapy for treating infections of influenza and COVID-19. The True Human antibodies targeting the virus causing COVID-19 were found to effectively neutralize a test virus at concentrations about four-times better than the antibodies the FDA is now considering for emergency use authorization.

Ongoing research found that the True Human antibodies in this therapeutic cocktail that target influenza are capable of rescuing 100% of animals that receive an otherwise lethal dose of flu virus. There is no other therapy available to treat both COVID-19 and Influenza infections that occur together.